Procyrion, Inc. Secures $57.7M Investment to Fast-Track Aortix™, a Revolutionary Cardiorenal Therapy Solution

Procyrion, Inc., a groundbreaking medical technology company, has successfully raised $57,700,000 in its latest funding round, marking a significant milestone in its quest to transform the treatment landscape for patients with cardiac and renal impairments. This notable capital infusion will accelerate the development of Procyrion’s innovative catheter-deployed pump technology, which addresses the unmet clinical needs of individuals suffering from cardiorenal syndrome. At the core of this technological advancement is Aortix™, a percutaneous mechanical circulatory support device designed to provide rapid, intra-aortic support through a minimally invasive catheter-based system. Currently, Aortix™ is in the research and development phase, with ongoing studies aimed at rigorously evaluating its safety and efficacy in managing complex cardiac and renal conditions. The new funds will be instrumental in expanding Procyrion’s robust clinical research efforts, enabling the company to conduct pivotal trials, refine its device technology, and engage with regulatory bodies to ensure compliance with federal investigational device mandates. In addition, the investment will support the scaling of manufacturing processes, the enhancement of research infrastructure, and the development of strategic partnerships that promise to expedite the translation of Aortix™ from investigational use to a widely adopted therapeutic option. Procyrion’s commitment to delivering transformative solutions is driven by the vision of improving patient outcomes and addressing the critical gaps in current medical treatment. As the company moves forward, its pioneering approach is set to redefine patient care, paving the way for a new era in the management of cardiorenal syndrome and reinforcing Procyrion’s role as a leader in medical innovation.